Su Yuanshuai, Zheng Qiuxian, Zhu Lingxiao, Gu Xinyu, Lu Juan, Li Lanjuan
State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, College of Medicine, National Clinical Research Center for Infectious Diseases, Zhejiang University, Hangzhou, 310003, China.
Cancer Cell Int. 2022 Mar 24;22(1):132. doi: 10.1186/s12935-022-02551-9.
MicroRNAs (miRNAs) are one type of noncoding RNAs that interfere with mRNA translation to downregulate gene expression, which results in posttranscriptional gene silencing. Over the past two decades, miRNAs have been widely reported to impact the progression of malignant tumours by interfering with cancer initiation and progression; therefore, miRNAs represent potential new diagnostic and therapeutic tools. miR-650 is a newly identified miR, and increasing studies have demonstrated that miR-650 plays critical roles in cancer progression, such as mediating the Wnt signalling pathway/AXIN1 (axis inhibition protein 1) axis in hepatocellular carcinoma. Nevertheless, associations between the expression patterns and molecular mechanisms of miR-650 in cancer have not been comprehensively described. In this article, we review the existing evidence regarding the mechanisms by which miR-650 expression is altered and their relation to cancer. Moreover, the promising clinical application of miR-650 for diagnosis and treatment is highlighted.
微小RNA（miRNA）是一类非编码RNA，可干扰mRNA翻译以下调基因表达，从而导致转录后基因沉默。在过去二十年中，广泛报道miRNA通过干扰癌症的起始和进展来影响恶性肿瘤的进程；因此，miRNA代表了潜在的新型诊断和治疗工具。miR-650是一种新发现的miRNA，越来越多的研究表明，miR-650在癌症进展中起关键作用，例如在肝细胞癌中介导Wnt信号通路/轴抑制蛋白1（AXIN1）轴。然而，miR-650在癌症中的表达模式与分子机制之间的关联尚未得到全面描述。在本文中，我们综述了有关miR-650表达改变的机制及其与癌症关系的现有证据。此外，还强调了miR-650在诊断和治疗方面有前景的临床应用。
